AnaptysBio, Inc. (NASDAQ:ANAB) Receives $41.45 Consensus Target Price from Analysts

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) have earned a consensus rating of “Moderate Buy” from the thirteen research firms that are covering the stock, Marketbeat Ratings reports. Four analysts have rated the stock with a hold recommendation, eight have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $40.08.

Several equities analysts recently commented on the stock. Wedbush reaffirmed an “outperform” rating and set a $40.00 price objective on shares of AnaptysBio in a research note on Monday. UBS Group boosted their price target on shares of AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. Wolfe Research assumed coverage on AnaptysBio in a research report on Tuesday. They set an “outperform” rating and a $25.00 target price for the company. Guggenheim lowered their price target on AnaptysBio from $90.00 to $36.00 and set a “buy” rating on the stock in a report on Thursday, December 12th. Finally, JPMorgan Chase & Co. dropped their price target on AnaptysBio from $66.00 to $36.00 and set an “overweight” rating for the company in a research report on Thursday, December 19th.

Insiders Place Their Bets

In other AnaptysBio news, Director Ecor1 Capital, Llc bought 6,646 shares of AnaptysBio stock in a transaction that occurred on Thursday, January 2nd. The shares were bought at an average price of $12.95 per share, with a total value of $86,065.70. Following the acquisition, the director now owns 7,880,094 shares in the company, valued at approximately $102,047,217.30. This trade represents a 0.08 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 33.70% of the company’s stock.

Institutional Trading of AnaptysBio

Institutional investors have recently added to or reduced their stakes in the business. FMR LLC increased its holdings in shares of AnaptysBio by 15.3% in the third quarter. FMR LLC now owns 3,309,175 shares of the biotechnology company’s stock worth $110,857,000 after buying an additional 438,557 shares during the period. Frazier Life Sciences Management L.P. increased its stake in AnaptysBio by 2.0% in the 3rd quarter. Frazier Life Sciences Management L.P. now owns 2,209,189 shares of the biotechnology company’s stock worth $74,008,000 after purchasing an additional 43,598 shares during the period. Assenagon Asset Management S.A. lifted its position in AnaptysBio by 55.1% in the third quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock valued at $15,927,000 after purchasing an additional 168,813 shares during the last quarter. Geode Capital Management LLC lifted its position in AnaptysBio by 3.0% in the third quarter. Geode Capital Management LLC now owns 465,401 shares of the biotechnology company’s stock valued at $15,594,000 after purchasing an additional 13,336 shares during the last quarter. Finally, Victory Capital Management Inc. boosted its stake in shares of AnaptysBio by 41.0% during the fourth quarter. Victory Capital Management Inc. now owns 334,450 shares of the biotechnology company’s stock valued at $4,428,000 after purchasing an additional 97,200 shares during the period.

AnaptysBio Stock Performance

Shares of NASDAQ ANAB opened at $16.08 on Friday. AnaptysBio has a fifty-two week low of $12.51 and a fifty-two week high of $41.31. The stock has a market cap of $489.30 million and a PE ratio of -2.64. The stock has a fifty day moving average of $16.87 and a 200-day moving average of $26.69.

AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The business had revenue of $30.02 million during the quarter, compared to analyst estimates of $7.92 million. On average, sell-side analysts predict that AnaptysBio will post -6.08 EPS for the current year.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.